Weekly treatment for alpha-1 antitrypsin deficiency-related emphysema
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests if a weekly medicine (Respreeza/Zemaira) can slow down lung damage in adults with alpha-1 antitrypsin deficiency (AATD) who have emphysema. Over 3 years, we will measure changes in lung density using CT scans to see if the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 65 years old
- You must have a confirmed diagnosis of emphysema caused by alpha-1 antitrypsin deficiency (AATD) with a specific genetic type (PiZZ, PiZ(null), or Pi(null/null))
- Your blood levels of alpha-1 antitrypsin must be low (below 11 micromolar or 50 mg/dL)
- You cannot have had a lung infection or a sudden worsening of your lung condition in the 6 weeks before starting the study
- You must not have had gene therapy for AATD before
- You must not have liver disease caused by AATD
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how alpha-1 antitrypsin deficiency affects the liver in adults. It aims to learn more about the liver problems caused by this condition and may help find better ways to manage them.
This trial tests a new treatment called BEAM-302, which aims to correct the genetic defect that causes alpha-1 antitrypsin deficiency. It may help prevent further lung and liver damage in people with the PiZZ mutation.
This study is looking at people with a specific mild form of alpha-1 antitrypsin deficiency (PiMZ) to understand how their lung disease progresses over time. It involves lung function tests and CT scans, and may help researchers learn more about the condition.
This study checks how safe a prescribed blood protein medicine (alpha-1 proteinase inhibitor) is over the long term in people with Alpha-1 antitrypsin deficiency. You may join if you already finished an earlier study or if your lung function has been declining.
This trial tests a gene therapy to fix the genetic cause of alpha-1 antitrypsin deficiency, aiming to stop or slow emphysema. It is for people with the most common harmful gene variants who have mild to moderate lung damage and are otherwise healthy enough to take steroids safely.
This study tests an experimental RNA-based medicine (AIR-001) for people with a genetic form of alpha-1 antitrypsin deficiency (AATD). It aims to see if the drug can help boost your body's own protective protein levels and may slow lung damage.
Hear when a new Alpha1-Antitrypsin Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.